Discontinuation of Levothyroxine Therapy for Patients With Subclinical Hypothyroidism

Exclusion Criteria

• •thyroid-stimulating hormone (TSH) \> 10 milli-international units per liter (mlU/L) (at any point)
• •Levothyroxine (LT4) dose more than 75 mcg daily
• •use of antithyroid medications, amiodarone, tyrosine kinase inhibitors or lithium
• •history of thyroidectomy or radioactive iodine therapy
• •LT4 suppressive therapy for thyroid cancer, goiter, or inflammation
• •pregnancy or plans for pregnancy in the next 6 months
• •an unstable medical condition that would jeopardize safety or interfere with study participation
• •severe hypothyroidism-related symptoms
• •strong family history of hypothyroidism
• •severe dyslipidemia
• •hospitalization for major illness within the previous 4 weeks
• •acute coronary artery syndrome, acute myocarditis, or pancarditis with the previous 12 months
• •grade IV New York Heart Association heart failure
• •receiving services from hospice
• •lack of decision-making capacity
• •terminal medical condition for which life expectancy would be less than 6 months
• •not willing to stop LT4
• •self-reported non-adherence to LT4 therapy
• •abnormal TSH at time of screening for participation (assessed during Baseline Visit)